Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the close of a EUR 90 million Series A funding round, bringing the total amount raised by the company to EUR 116 million.
Additionally, investors should not forget that J.P. Morgan's exposure to macroeconomic cycles leaves it vulnerable to credit quality deterioration and reduced loan demand if economic growth falters.
The top recommendations for 2025 made by J.P. Morgan's equities analysts highlight exceptional technology businesses with strong investment potential throughout the industry. Aramark (NYSE ...
Focusing on companies in small, medium, and large-cap cap businesses, J.P. Morgan analysts have ranked their top stock recommendations in the broader Internet space for 2025. The study shows how ...
Morgan Stanley stays bullish on Apple going into 2025, citing accelerated iPhone replacement cycles, double-digit services ... Among active stocks. J.P. Morgan upgraded Okta (OKTA) to Overweight ...
The American industrialist and financier John Pierpont Morgan (1837-1913) was a serious collector of objects, books, and ephemera for most of his life, and his avidity and the diversity of the mat ...
We may receive commissions on purchases made from our chosen links. J.P. Morgan Personal Advisors is a service that provides clients with a team of financial advisors to manage their investments.